AUG 24, 2020 10:08 AM PDT

Injectable Drug Stops HIV From Entering Cells

WRITTEN BY: Tara Fernandez


Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself with the T cell’s membrane before injecting its genetic material into the cell’s core. Next, the viral RNA is converted to a DNA format before the host cell’s machinery is hijacked to produce multiple new copies of the virus.

A collaborative effort led by University of Utah Health researchers has resulted in a new experimental treatment to block the first step in HIV infection: its entry into T cells. This new drug promises significant advantages over existing “cocktail” treatments including longer-lasting effects and fewer adverse side effects. The study was published in Proceedings of the National Academy of Sciences (PNAS).

Michael S. Kay, senior author and professor of biochemistry said, "This is an exciting new HIV therapeutic option for both prevention and treatment, with a unique mechanism of action compared to other approved drugs." 

HIV, the virus that causes AIDS, is among the biggest, toughest challenges in global health with approximately 38 million people worldwide with HIV/AIDS in 2019. The current standard of care involves combination antiretroviral therapy, or cART, a cocktail of drugs that improves the quality of life for the patients that take it. The downsides of this form of treatment, however, are that it’s expensive, needs to be taken daily, has serious side effects, and frequent HIV mutations mean the possibility of drug resistance.

The newly-developed drug, called CPT31 was inspired by a natural peptide that fuses to a pocket in HIV’s fusion machinery — a region not prone to mutation. CPT31 is a D-peptide, a type of protein that, due to its molecular conformation, makes it optimal for use in long-acting injectable drug formulations. This would make taking a daily regimen of pills a thing of the past for HIV patients.

"In addition to their durability in the body, D-peptides are largely ignored by the immune system, preventing immune reactions that are a side effect often seen with traditional peptide and protein drugs," said Brett Welch, a co-author on the study.

The scientists see the potential for CPT31 being not only a therapeutic for HIV but also as a prophylactic, or preventative, therapy.

"We think this drug could be used by itself to prevent HIV infection because initial HIV exposure typically involves a relatively small amount of virus," said Kay.

 

Sources: PNAS, Medical Xpress.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 17, 2020
Coronavirus
Substantial Antiviral Response Seen in Adults Recovered from COVID-19
MAY 17, 2020
Substantial Antiviral Response Seen in Adults Recovered from COVID-19
Some good news comes as researchers scramble for potential vaccine candidates amidst the global COVID-19 pandemic. Scien ...
JUL 14, 2020
Immunology
Itsy Bitsy Nanobodies to Defeat the Big Bad Coronavirus
JUL 14, 2020
Itsy Bitsy Nanobodies to Defeat the Big Bad Coronavirus
Scientists are working on developing an arsenal of nano-sized weapons in the war against COVID-19. These molecules, call ...
JUL 30, 2020
Immunology
Sunshine Could Lower Your Risk of Developing MS
JUL 30, 2020
Sunshine Could Lower Your Risk of Developing MS
In multiple sclerosis, or MS, the insulating sheaths around nerve cells in the brain and spinal cord called myelin becom ...
JUL 26, 2020
Genetics & Genomics
MAIT Cell Disappearance is Connected to a Genetic Mutation
JUL 26, 2020
MAIT Cell Disappearance is Connected to a Genetic Mutation
Mucosal-associated invariant T cells appear to be a critical part of the human immune system, and dysfunction in these c ...
JUL 29, 2020
Immunology
Immune Variation Explains Different COVID-19 Outcomes
JUL 29, 2020
Immune Variation Explains Different COVID-19 Outcomes
Immune systems respond differently to coronavirus infection. People experience the disease causes by coronavirus, COVID- ...
SEP 07, 2020
Immunology
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
SEP 07, 2020
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
The ability to edit the human genome using CRISPR has been heralded as a revolution in medicine. However, one of the big ...
Loading Comments...